Financial Performance - Revenue for the quarter ended December 2024 was $2.41 billion, a 25.2% year-over-year increase [1] - EPS for the quarter was $2.21, compared to $1.60 a year ago, representing a 38.1% increase [1] - Revenue matched the Zacks Consensus Estimate of $2.41 billion, with a surprise of -0.02% [1] - EPS exceeded the consensus estimate of $1.77 by 24.86% [1] Stock Performance - Shares of Intuitive Surgical returned +13.7% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently has a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Key Metrics - Da Vinci Surgical System Installed Base: 9,902, slightly below the 9,912 average estimate [4] - Total System Units Placed - Total Company: 493, exceeding the 434 average estimate [4] - Total System Units Placed - United States: 284, surpassing the 208 average estimate [4] - Total System Units Placed - Outside of the United States: 209, slightly above the 207 average estimate [4] Revenue Breakdown - Revenue- Product (Instruments and accessories and Systems): $2.07 billion, a 27.2% year-over-year increase, exceeding the $1.85 billion estimate [4] - Revenue- Services: $347.40 million, a 14.1% year-over-year increase, slightly above the $345.32 million estimate [4] - Revenue- Systems: $654.60 million, a 36.3% year-over-year increase, surpassing the $504.39 million estimate [4] - Revenue- Instruments and accessories: $1.41 billion, a 23.4% year-over-year increase, exceeding the $1.35 billion estimate [4]

Earnings Performance - Intuitive Surgical reported quarterly earnings of $2 21 per share, beating the Zacks Consensus Estimate of $1 77 per share, representing a 24 86% earnings surprise [1] - The company's earnings per share (EPS) increased from $1 60 per share a year ago, with adjustments for non-recurring items [1] - Over the last four quarters, the company has surpassed consensus EPS estimates four times [2] Revenue Performance - Intuitive Surgical posted revenues of $2 41 billion for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0 02% [2] - Year-over-year revenues increased from $1 93 billion, and the company has topped consensus revenue estimates three times over the last four quarters [2] Stock Performance and Market Comparison - Intuitive Surgical shares have gained approximately 17% since the beginning of the year, outperforming the S&P 500's gain of 3 5% [3] - The stock's immediate price movement sustainability will depend on management's commentary during the earnings call [3] Earnings Outlook and Estimate Revisions - The current consensus EPS estimate for the coming quarter is $1 78 on $2 2 billion in revenues, and $7 87 on $9 55 billion in revenues for the current fiscal year [7] - The estimate revisions trend for Intuitive Surgical is mixed, translating into a Zacks Rank 3 (Hold), indicating expected market-aligned performance [6] Industry Context - Intuitive Surgical belongs to the Zacks Medical - Instruments industry, which is currently in the top 26% of the 250 plus Zacks industries [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Glaukos, another company in the Medical - Instruments industry, is expected to post a quarterly loss of $0 43 per share, representing a year-over-year improvement of 31 8% [9] - Glaukos' revenues are expected to be $100 75 million, up 22 3% from the year-ago quarter [9]

Earnings Performance - Intuitive Surgical reported Q4 revenue of $2 41 billion, a 25% YoY increase, surpassing analyst consensus [1] - Q4 earnings were $686 million, or $1 88 per share, up from $606 million, or $1 69 per share, a year ago, beating expectations [1] Procedure and System Growth - Procedures performed with da Vinci surgical devices increased 18% YoY [2] - The company installed 493 da Vinci systems in Q4, compared to 415 a year ago [2] Future Outlook - The company expects da Vinci procedures to grow 13% to 16% in 2024 [3] - Adjusted gross profit margin is expected to decline by 1 to 2 percentage points, excluding potential new tariffs which could have a material impact [3] Stock Performance - Intuitive Surgical shares fluctuated slightly in extended trading after the earnings release [4] - The stock closed at an all-time high the previous day and has gained approximately 62% over the past year [4]

Intuitive Surgical (ISRG) stock skidded late Thursday despite beating profit expectations following a strong sales preannouncement that sent shares on a five-day sprint. During the December quarter, the robotic surgery giant earned an adjusted $2.21 per share, easily beat forecasts for $1.79 a share, according to FactSet. The rest of Intuitive Surgical's report lined up with the preannouncement on Jan. 15 that sent Intuitive Surgical stock flying 7.7%.But in after-hours trades on today's stock market, share ...

Shares of robotic surgery pioneer Intuitive Surgical (ISRG -0.29%) have been soaring lately. A preliminary look at sales results from the fourth quarter of 2024 suggests its business is on the right track.Intuitive Surgical's recent performance and forward outlook are outstanding, and investors have noticed. Shares of the well-established medical technology business rose 62% during the 12-month period that ended Jan. 22, 2025.Is it still a good time to buy Intuitive Surgical, or has it risen too far already ...

Revenue Growth - Total revenue for Q4 2024 increased by 25% to $2,413.5 million compared to $1,928.3 million in Q4 2023[2] - Instruments and accessories revenue grew by 23% to $1,411.5 million in Q4 2024 from $1,143.7 million in Q4 2023[2] - Recurring revenue accounted for 80% of total revenue in Q4 2024, slightly down from 82% in Q4 2023[2] System Placements - Da Vinci Surgical System placements in the US increased by 36% to 284 units in Q4 2024 from 209 units in Q4 2023[2] - Da Vinci SP Systems placements surged by 58% to 30 units in Q4 2024 from 19 units in Q4 2023[2] - Ion System placements rose by 57% to 69 units in Q4 2024 from 44 units in Q4 2023[2] - The installed base of Da Vinci Surgical Systems increased by 15% to 9,902 units in 2024 from 8,606 units in 2023[2] - Average selling price of systems increased by 12% to $1.59 million in Q4 2024 from $1.42 million in Q4 2023[2] Procedure Growth - Total worldwide procedures increased by 17% to 2,683 thousand in 2024 from 2,286 thousand in 2023[4] - General Surgery procedures outside the US grew by 35% to 254 thousand in 2024 from 188 thousand in 2023[4]

Intuitive Surgical, Inc. ISRG is announcing its fourth-quarter earnings on Thursday. Wall Street expects $1.79 in EPS and $2.25 billion in revenues as the company reports after market hours.The stock is up 63.75% over the past year, 16.06% YTD. Intuitive Surgical enters earnings season at record highs, with shares recently hitting an all-time high of $615.99. The company's expansion in southern Europe, acquiring da Vinci and Ion distribution businesses, strengthens its direct presence and customer reach. CE ...

Core Viewpoint - Intuitive Surgical, Inc. (ISRG) is expected to report strong fourth-quarter 2024 earnings, with sales projected at $2.41 billion, reflecting a 25% year-over-year increase, and earnings per share estimated at $1.77 [1][5]. Earnings Estimates - The Zacks Consensus Estimate for ISRG's sales and earnings is $2.41 billion and $1.77 per share, respectively [1]. - Earnings per share estimates for 2024 and 2025 have increased to $6.67 and $7.66, respectively, over the past 30 days [1]. Recent Performance - In the last reported quarter, ISRG achieved an earnings surprise of 11.52%, beating estimates in each of the trailing four quarters with an average surprise of 10.96% [3]. Earnings Prediction - The company has an Earnings ESP of 7.29% and a Zacks Rank of 3 (Hold), indicating a favorable outlook for an earnings beat [4]. Sales Growth Factors - Preliminary sales of $2.41 billion for Q4 2024 indicate a 25% year-over-year growth, driven by strong procedure performance and capital placements [5]. - Instruments and accessories revenues are expected to be approximately $1.41 billion, up 23% year over year, with da Vinci procedures increasing by 18% [6]. Market Trends - General surgery procedures in the U.S. and cancer procedures in ex-U.S. markets have contributed to procedure growth [9]. - China's recovery post-COVID and rising adoption in Japan and India are expected to boost sales [10]. System Placements - ISRG placed 174 da Vinci 5 systems in the U.S., reflecting nearly 60% sequential growth [11]. - Strong system placements in the Asia-Pacific region are also anticipated, although placements in China may face challenges [11]. Margin Expectations - Margins are likely to improve due to cost reductions and lower freight rates, despite an expected increase in depreciation expenses [13]. Stock Performance - ISRG shares have appreciated 31.3% over the past six months, outperforming the industry and S&P 500 [14]. - The current forward 12-month P/E ratio is 93.03X, significantly higher than the industry average of 33.14X, indicating a premium valuation [17]. Investment Outlook - Despite high valuation, ISRG is expected to continue strong performance driven by da Vinci procedure volume growth and improved system placements [20]. - The launch of new systems in Europe and the U.S. is expected to drive further growth, although challenges in bariatric procedures and China may offset some gains [21].

Company Overview - Intuitive Surgical is a healthcare company specializing in robotic-assisted surgical devices, particularly the da Vinci surgical systems, which enable minimally invasive and precise procedures [1] - The company's devices are costly, with prices upwards of $2 million, leading many customers to opt for leasing instead of purchasing [2] Financial Performance - Preliminary Q4 2024 results show revenue of $2.4 billion, a 25% increase from the same period last year [3] - Full-year 2024 revenue is expected to reach $8.4 billion, a 17% increase from the $7.1 billion reported in 2023 [3] - The company has shown strong recovery and growth after pandemic-related disruptions [4] Market and Industry Outlook - The surgical robots market is projected to grow at a compounded annual growth rate of 9.5% until 2030, reaching a global market value of $7.4 billion, up from $4.3 billion in the previous year [4] - The market has significant long-term growth potential as healthcare technologies advance [4] Valuation and Investment Considerations - Intuitive Surgical's stock has rallied, increasing by around 60% over the past 12 months [3] - The stock is expensive, with a price-to-earnings multiple of 95 and a price/earnings-growth multiple over 4, indicating a high valuation [5] - The company's market cap exceeds $210 billion, reflecting a rich valuation [6] - Despite the high valuation, the company's long-term growth potential remains strong, driven by the increasing demand for robotic surgical devices [6][7] - Investors should consider a long-term holding period (10-plus years) to realize potential gains, as short-term gains may be limited due to the stock's high price [7]

Core Insights - Intuitive plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino through the acquisition of da Vinci and Ion distribution businesses in these regions [1][2] - The acquisition is subject to regulatory approvals and is expected to close in 2026 [2][3] - The integration of the acquired businesses will enhance Intuitive's understanding of customer needs and improve patient access to minimally invasive care [3][4] Company Strategy - The acquisition aligns with Intuitive's strategy to invest in expanding its footprint in Europe and to deepen customer relationships [3][4] - Intuitive aims to leverage its direct presence to optimize care delivery and support better patient outcomes [6] Business Operations - Upon completion of the deal, the da Vinci and Ion businesses will be wholly owned by Intuitive and integrated into its European commercial and marketing organization [3][4] - The leadership of the acquired companies has played a significant role in establishing robotic technology in Europe, which will be continued post-acquisition [4][5]